NexMed expands patent protection for Prostaglandin E1 -based products in Israel

NexMed, Inc. (Nasdaq: NEXM), backed by a revenue generating CRO business and seeking to leverage its proprietary, multi-route NexACT^® drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, today announced that the Israel Patent Office has issued an allowance notice for NexMed's patent application entitled, "Topical Compositions for Prostaglandin E₁ Delivery." The patent, when issued, will provide coverage to May 13, 2019, and expand the protection of NexMed's Prostaglandin E₁ (alprostadil)-based products in Israel to seven granted patents. NexMed has several alprostadil-based treatments under development, including Vitaros^®, for the treatment of erectile dysfunction; Femprox^®, for female sexual arousal disorder, and RayVa^™, for Raynaud's syndrome.

“This addition to our patent portfolio strengthens our intellectual property position and bolsters our ongoing partnering discussions for the licensing of our products in Israel and the Middle East.”

Commenting on today's news, Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, stated, "This addition to our patent portfolio strengthens our intellectual property position and bolsters our ongoing partnering discussions for the licensing of our products in Israel and the Middle East."